A prospective, multi-centre, open-label study to establish the equipotent dose ratio after switching from strong opioids to Transtec® in subjects with pain due to cancer

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-004624-13

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to establish clinically meaningful equipotency ratios between buprenorphine administered primarily transdermally and the strong opioids, morphine, oxycodone and fentanyl.


Critère d'inclusion

  • Cancer Pain